Healthcare Companies Have Three Reasons to Grow

VIDEO: Pictet's Michael Söjström discusses what impact the US healthcare reform, population aging and emerging markets growth will have on biotech and generics

Fernando Luque 15 March, 2011 | 9:14AM
Facebook Twitter LinkedIn

Fernando Luque, editor of Morningstar.es, a sister site of Morningstar.co.uk, talks to Michael Sjöström, manager of the Pictet Biotech and Pictet Generics funds about how the US healthcare reform as well as broader demographic and economic trends could influence investments in healthcare. Healthcare companies grow due to three factors – aging population in developed markets, accumulation of wealth in emerging markets and innovation, says Söjstrom. The biotech and generic segment of the market are influenced to a different degree by these factors, he explains. 

 

Fernando Luque: Hello, I'm Fernando Luque, Editor for Morningstar and I am joined today by Michael Söjstrom, manager of the Pictet Biotech and also manager of the Pictet Generics. We are going to discuss both funds with Michael. Michael, thank you for being here.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

Fernando Luque

Fernando Luque  is Senior Financial Editor at Morningstar Spain